TY - JOUR
T1 - Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients
T2 - A multinational, multicenter, prospective registry study in Asia
AU - Yoon, Sang Eun
AU - Song, Yuqin
AU - Kim, Seok Jin
AU - Yoon, Dok Hyun
AU - Chen, Tsai Yun
AU - Koh, Youngil
AU - Kang, Ka Won
AU - Lee, Ho Sup
AU - Tay, Kevin Kuang Wei
AU - Lim, Soon Thye
AU - Poon, Michele
AU - Irawan, Cosphiadi
AU - Zhao, Weili
AU - Do, Young Rok
AU - Lee, Mark Hong
AU - Ng, Soo Chin
AU - Lee, Won Sik
AU - Guo, Ye
AU - Zhang, Huilai
AU - Kang, Hye Jin
AU - Yun, Hwan Jung
AU - Kim, Hyo Jung
AU - Lung, Daryl Tan Chen
AU - Kwak, Jae Yong
AU - Han, Jae Joon
AU - Mun, Yeung Chul
AU - Oh, Sung Yong
AU - Shim, Hyeok
AU - Kwon, Jung Hye
AU - Sohn, Byeong Seok
AU - Park, Seong Kyu
AU - Jo, Jae Cheol
AU - Ko, Young Hyeh
AU - Jun, Zhu
AU - Kim, Won Seog
N1 - Publisher Copyright:
© 2021
PY - 2021/5
Y1 - 2021/5
N2 - Background: Peripheral T-cell lymphomas (PTCLs) are uncommon and their frequency is regionally heterogeneous. Several studies have been conducted to evaluate the clinical features and treatment outcomes of this disease entity, but the majority of these were conducted in limited areas, making it difficult to comprehensively analyze their relative frequency and clinical features. Furthermore, no consensus treatment for PTCLs has been established. Therefore, we conducted an Asia-specific study to understand the relative frequency of PTCLs and assess treatments and their outcomes in Asian patients. Methods: We performed a multinational, multicenter, prospective registry of adult patients with PTCLs that was named as the International Cooperative non-Hodgkin T-cell lymphoma prospective registry study where thirty-two institutes from six Asian countries and territories (Korea, China, Taiwan, Singapore, Malaysia, and Indonesia) participated. Findings: A total of 486 patients were registered between April 2016 and February 2019, and more than a half of patients (57%) had stage III or IV. Extranodal natural killer (NK)/T- cell lymphoma was the most common subtype (n = 139,28.6%), followed by angioimmunoblastic T-cell lymphoma (AITL, n = 120,24.7%), PTCL-not otherwise specified (PTCL-NOS, n = 101,20.8%), ALK-positive anaplastic large cell lymphoma (ALCL, n = 34,6.9%), and ALK-negative ALCL (n = 30,6.2%). The median progression-free survival (PFS) and overall survival (OS) were 21.1 months (95% CI,10.6–31.6) and 83.6 months (95% CI, 56.7–110.5), respectively. Upfront use of combined treatment with chemotherapy and radiotherapy showed better PFS than chemotherapy alone in localized ENKTL whereas consolidation with upfront autologous stem cell transplantation (SCT) provided longer PFS in advance stage ENKTL. In patients with PTCLs other than ENKTL, anthracycline-containing chemotherapies were widely used, but the outcome of those regimens was not satisfactory, and upfront autologous SCT was not significantly associated with survival benefit, either. The treatment outcome of salvage chemotherapy was disappointing, and none of the salvage strategies showed superiority to one another. Interpretation: This multinational, multicenter study identified the relative frequency of each subtype of PTCLs across Asian countries, and the survival outcomes according to the therapeutic strategies currently used.
AB - Background: Peripheral T-cell lymphomas (PTCLs) are uncommon and their frequency is regionally heterogeneous. Several studies have been conducted to evaluate the clinical features and treatment outcomes of this disease entity, but the majority of these were conducted in limited areas, making it difficult to comprehensively analyze their relative frequency and clinical features. Furthermore, no consensus treatment for PTCLs has been established. Therefore, we conducted an Asia-specific study to understand the relative frequency of PTCLs and assess treatments and their outcomes in Asian patients. Methods: We performed a multinational, multicenter, prospective registry of adult patients with PTCLs that was named as the International Cooperative non-Hodgkin T-cell lymphoma prospective registry study where thirty-two institutes from six Asian countries and territories (Korea, China, Taiwan, Singapore, Malaysia, and Indonesia) participated. Findings: A total of 486 patients were registered between April 2016 and February 2019, and more than a half of patients (57%) had stage III or IV. Extranodal natural killer (NK)/T- cell lymphoma was the most common subtype (n = 139,28.6%), followed by angioimmunoblastic T-cell lymphoma (AITL, n = 120,24.7%), PTCL-not otherwise specified (PTCL-NOS, n = 101,20.8%), ALK-positive anaplastic large cell lymphoma (ALCL, n = 34,6.9%), and ALK-negative ALCL (n = 30,6.2%). The median progression-free survival (PFS) and overall survival (OS) were 21.1 months (95% CI,10.6–31.6) and 83.6 months (95% CI, 56.7–110.5), respectively. Upfront use of combined treatment with chemotherapy and radiotherapy showed better PFS than chemotherapy alone in localized ENKTL whereas consolidation with upfront autologous stem cell transplantation (SCT) provided longer PFS in advance stage ENKTL. In patients with PTCLs other than ENKTL, anthracycline-containing chemotherapies were widely used, but the outcome of those regimens was not satisfactory, and upfront autologous SCT was not significantly associated with survival benefit, either. The treatment outcome of salvage chemotherapy was disappointing, and none of the salvage strategies showed superiority to one another. Interpretation: This multinational, multicenter study identified the relative frequency of each subtype of PTCLs across Asian countries, and the survival outcomes according to the therapeutic strategies currently used.
KW - Extranodal NK-T-Cell
KW - Frequency
KW - Lymphoma
KW - Peripheral
KW - Prognosis
KW - Survival
KW - T-Cell
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85103753852&partnerID=8YFLogxK
U2 - 10.1016/j.lanwpc.2021.100126
DO - 10.1016/j.lanwpc.2021.100126
M3 - Article
AN - SCOPUS:85103753852
SN - 2666-6065
VL - 10
JO - The Lancet Regional Health - Western Pacific
JF - The Lancet Regional Health - Western Pacific
M1 - 100126
ER -